Zynga (ZNGA) closed at $9.18 in the latest trading session, marking a -1.61% move from the prior day. This change was narrower than the S&P 500's daily loss of 5.89%. At the same time, the Dow lost 6.9%, and the tech-heavy Nasdaq lost 5.27%.
Moderna (MRNA) closed the most recent trading day at $60.20, moving +0.22% from the previous trading session. The stock outpaced the S&P 500's daily loss of 5.89%. Elsewhere, the Dow lost 6.9%, while the tech-heavy Nasdaq lost 5.27%.
Novavax (NVAX) closed the most recent trading day at $44.43, moving -1.18% from the previous trading session. This change was narrower than the S&P 500's 5.89% loss on the day. Elsewhere, the Dow lost 6.9%, while the tech-heavy Nasdaq lost 5.27%.
PVH (PVH) came out with a quarterly loss of $3.03 per share versus the Zacks Consensus Estimate of a loss of $1.81. This compares to earnings of $2.46 per share a year ago. These figures are adjusted for non-recurring items.
Lululemon (LULU) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.
A month into efforts to broadly reopen the U.S. economy there is little clarity either on the pace and durability of the recovery, or on the ability to convincingly suppress the virus that has killed more than 112,000 Americans.
New Bank of Canada Governor Tiff Macklem, already facing the double whammy of the coronavirus pandemic and slumping oil prices, must now also contend with the Federal Reserve forecast that the United States expects years of slow growth.
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Toda
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Toda
In trading on Thursday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) crossed below their 200 day moving average of $31.22, changing hands as low as $30.53 per share. Apellis Pharmaceuticals Inc shares are currently trading down about 1.5% on the day. The chart below
In trading on Thursday, shares of Industrial Logistics Properties Trust (Symbol: ILPT) crossed below their 200 day moving average of $20.42, changing hands as low as $19.03 per share. Industrial Logistics Properties Trust shares are currently trading off about 6.2% on the day
There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on June 2, CME Group's Director, William R. Shepard, invested $137,315.10 into 771 shares of CME, for a cost per share of $178.10. Bar
In trading on Thursday, shares of Tabula Rasa HealthCare Inc (Symbol: TRHC) crossed below their 200 day moving average of $52.94, changing hands as low as $52.77 per share. Tabula Rasa HealthCare Inc shares are currently trading down about 5% on the day. The chart below show
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Micron Technology Inc. (Symbol: MU), where a total volume of 133,144 contracts has been traded thus far today, a contract volume which is representative of appr
Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Starbucks Corp. (Symbol: SBUX), where a total volume of 92,741 contracts has been traded thus far today, a contract volume which is representative of approximat
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Procter & Gamble Company (Symbol: PG), where a total of 33,314 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts
Bristol-Myers BMY announced that the FDA has approved blockbuster immuno-oncology drug, Opdivo, for yet another indication.The drug is now approved for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after p
Checked
17 minutes 55 seconds ago
This feed is responsible for generating the rss feed related to the topic Stocks